Waltham, United States
Mercy BioAnalytics, Inc. is a groundbreaking biotechnology startup based in the United States that is dedicated to revolutionizing cancer detection. The company's slogan, "We are making early stage cancer easier to find," succinctly captures their mission. Founded in 2018, Mercy BioAnalytics has garnered significant attention and recently received a noteworthy $41.00M Series A investment on 03 April 2023. This substantial funding was provided by an impressive consortium of investors including Broadway Angels, Hatteras Venture Partners, iSelect, LabCorp, Novalis LifeSciences, Sozo Ventures, Bruker, and the American Cancer Society.
The company's core focus is on the early detection of cancer, striving to save lives and alleviate suffering worldwide. Their innovative approach involves the development of a liquid biopsy assay platform that analyzes tumor-derived extracellular vesicles abundant in blood. These vesicles carry crucial information about their cell of origin, enabling the detection of cancer even in its earliest stages. Through their groundbreaking technology and influential network of investors, Mercy BioAnalytics is poised to make a significant impact in the fight against cancer.
